Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Intel Strategy for Achieving Wealth and Off Topic -- Ignore unavailable to you. Want to Upgrade?

To: Frank Ellis Morris who wrote (14928)	12/22/1997 11:39:00 AM
From: Ann Janssen	Read Replies (2) \| Respond to of 27012

Good Morning Frank, Happy Holidays!! And THANK YOU for starting these threads and getting all of us together!!! Now On topic. I saw Cramer on Good morning America this morning and he thinks we'll have a good week. 2 things he saw this weekend he liked. 1 - Coke thinks they can take advantage of this asia crisis and 2 - Goldman Sachs purchased 3 Billion worth of Japans loans. Have a Great Day and Take Care Ann

To: Frank Ellis Morris who wrote (14928)	12/22/1997 4:14:00 PM
From: Sonki	Read Replies (1) \| Respond to of 27012

add 3% to revenue stock up 3%(MRK) 105 5/8 +3. This drug maker is getting a big push from investors today after the FDA approved Propecia, its drug that stops hair loss and encourages hair growth. While the drug does have some side-effects in around 2% of the patients that participated in the study, men are willing to try just about anything, even if it means lowering a person's sexual drive, in order to halt and reverse the trend in hair loss. The one-a-day pill is expected to cost between $45 and $49 for a monthly prescription supply and will be available to men only as studies have shown Propecia to cause birth defects in women. Propecia is expected to go head-to-head against Rogaine (PNU 36 5/8 +5/8), which is the only other FDA approved treatment available to fight hair loss. Given that there are an estimated 3 million users of Rogaine at the moment, if Merck is able to get about half this market to switch to its product, at $45 per month, the company could be generating as much as $810 million in additional revenues from Propecia. Of course, PNU will not stand still, and the added marketing costs will eat into the profits, but it seems that Merck could have a nice winner in this drug, even though the drug is not known to prevent hair loss from men who lose hair from the temples. Merck is on track to generate revenues of more than $23.7 billion in the current fiscal year from its global operations. Thus the 3% or more in additional revenues from this new drug could be significant if only the company can manage to have a good portion fall to the bottom line.